J Rheum Dis.  2021 Apr;28(2):55-59. 10.4078/jrd.2021.28.2.55.

Axial Spondyloarthritis: Current Advances, Future Challenges

• Inman RD

• KMID: 2514115
• DOI: http://doi.org/10.4078/jrd.2021.28.2.55

Abstract

Axial spondyloarthritis (axSpA) is a chronic inflammatory joint disease with a predilection for the spine. It affects young adults and has the potential to have a major impact on quality of life, not only because of the chronic pain and fatigue, but also because of the potential for marked disability related to spinal ankylosis. Early detection of axSpA remains a major challenge, for which there is a heightened sense of urgency since it has been shown that earlier intervention with biologics can alter the progression of radiographic change in the spine. Advances in the genetics of axSpA have highlighted a number of candidate genes conferring susceptibility to the disease, but there is evidence of environmental factors playing a role as well. Recently studies in both clinical and experimental axSpA have implicated alterations in the gut microbiome as playing a key role, and the immunology of the gut-joint axis is becoming better understood. The unmet needs which are shaping the research agenda include improvement in early case identification, sensitive and specific biomarkers which could accurately reflect disease activity and severity, improved understanding of the common pathways of inflammation in the skin, eye and gut in axSpA, and novel therapeutic targets which could have curative potential.

Keyword

Spondylitis; Ankylosing spondylitis; Unmet needs

Reference

1. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. 2013; The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 65:2645–54. DOI: 10.1002/art.38070. PMID: 23818109. PMCID: PMC3974160.

2. Koo BS, Oh JS, Park SY, Shin JH, Ahn GY, Lee S, et al. 2020; Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. Ann Rheum Dis. 79:1327–32. DOI: 10.1136/annrheumdis-2019-216741. PMID: 32660979.

3. Tsui FW, Tsui HW, Las Heras F, Pritzker KP, Inman RD. 2014; Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis. 73:1873–9. DOI: 10.1136/annrheumdis-2013-203630. PMID: 23894062.

4. Akram A, Lin A, Gracey E, Streutker CJ, Inman RD. 2014; HLA-B27, but not HLA-B7, immunodominance to influenza is ERAP dependent. J Immunol. 192:5520–8. DOI: 10.4049/jimmunol.1400343. PMID: 24835397.

5. Tavasolian F, Rashidi M, Hatam GR, Jeddi M, Hosseini AZ, Mosawi SH, et al. 2021; HLA, immune response, and susceptibility to COVID-19. Front Immunol. 11:601886. DOI: 10.3389/fimmu.2020.601886. PMID: 33488597. PMCID: PMC7820778.

6. Danoy P, Pryce K, Hadler J, Bradbury LA, Farrar C, Pointon J, et al. 2010; Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet. 6:e1001195. DOI: 10.1371/journal.pgen.1001195. PMID: 21152001. PMCID: PMC2996314.

7. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernández-Sueiro JL, et al. 1994; The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 180:2359–64. DOI: 10.1084/jem.180.6.2359. PMID: 7964509. PMCID: PMC2191772.

8. Yin J, Sternes PR, Wang M, Song J, Morrison M, Li T, et al. 2020; Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann Rheum Dis. 79:132–40. DOI: 10.1136/annrheumdis-2019-215763. PMID: 31662318.

9. Tito RY, Cypers H, Joossens M, Varkas G, Van Praet L, Glorieus E, et al. 2017; Brief Report: Dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol. 69:114–21. DOI: 10.1002/art.39802. PMID: 27390077.

10. Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiocchia G, et al. 2017; Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 76:1614–22. DOI: 10.1136/annrheumdis-2016-211064. PMID: 28606969.

11. Asquith M, Davin S, Stauffer P, Michell C, Janowitz C, Lin P, et al. 2017; Intestinal metabolites are profoundly altered in the context of HLA-B27 expression and functionally modulate disease in a rat model of spondyloarthritis. Arthritis Rheumatol. 69:1984–95. DOI: 10.1002/art.40183. PMID: 28622455. PMCID: PMC5623151.

12. Chriswell ME, Kuhn KA. 2019; Microbiota-mediated mucosal inflammation in arthritis. Best Pract Res Clin Rheumatol. 33:101492. DOI: 10.1016/j.berh.2020.101492. PMID: 32151461. PMCID: PMC7709780.

13. Qaiyum Z, Gracey E, Yao Y, Inman RD. 2019; Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis. Ann Rheum Dis. 78:1566–75. DOI: 10.1136/annrheumdis-2019-215349. PMID: 31471299.

14. Varkas G, Thevissen K, De Brabanter G, Van Praet L, Czul-Gurdian F, Cypers H, et al. 2017; An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis. 76:878–81. DOI: 10.1136/annrheumdis-2016-210233. PMID: 27899374.

15. Gracey E, Qaiyum Z, Almaghlouth I, Lawson D, Karki S, Avvaru N, et al. 2016; IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis. 75:2124–32. DOI: 10.1136/annrheumdis-2015-208902. PMID: 27165176.

16. Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, et al. 2018; Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 77:1295–302. DOI: 10.1136/annrheumdis-2018-213328. PMID: 29945918. PMCID: PMC6104676.

17. O'Shea FD, Boyle E, Salonen DC, Ammendolia C, Peterson C, Hsu W, et al. 2010; Inflammatory and degenerative sacroiliac joint disease in a primary back pain cohort. Arthritis Care Res (Hoboken). 62:447–54. DOI: 10.1002/acr.20168. PMID: 20391497.

18. Passalent L, Hawke C, Lawson DO, Omar A, Alnaqbi KA, Wallis D, et al. 2020; Advancing early identification of axial spondyloarthritis: an interobserver comparison of extended role practitioners and rheumatologists. J Rheumatol. 47:524–30. DOI: 10.3899/jrheum.180787. PMID: 31043543.

19. Ranganathan V, Ciccia F, Zeng F, Sari I, Guggino G, Muralitharan J, et al. 2017; Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis. Arthritis Rheumatol. 69:1796–806. DOI: 10.1002/art.40175. PMID: 28597514.

20. Gracey E, Hromadová D, Lim M, Qaiyum Z, Zeng M, Yao Y, et al. 2020; TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis. J Clin Invest. 130:1863–78. DOI: 10.1172/JCI126567. PMID: 32149730. PMCID: PMC7108927.

21. Jo S, Won EJ, Kim MJ, Lee YJ, Jin SH, Park PR, et al. 2020; Nov. 25. STAT3 phosphorylation inhibition for treating inflammation and new bone formation in ankylosing spondylitis. Rheumatology (Oxford). [Epub]. DOI: 10.1093/rheumatology/keaa846. PMID: 33237331.